Genomic Applications Partnership Program (GAPP)
GAPP Investment Strategy and Guidelines
Expression of Interest Forms
GAPP Full Proposal Forms
Investment Strategy and Guidelines
Update to GAPP Application Process
The Genomic Applications Partnership Program (GAPP) represents a key element in Genome Canada’s strategic plan towards
funding downstream research and development (R&D) projects that are driven by challenges and opportunities facing
users of genomics based technologies. For the purpose of this program, “Users” include the various stakeholders that
have an interest in “pulling” technologies and other results of genomics research from academia to market and application,
including industry, government, not-for-profits, and other organizations.
Genome Canada is a catalyst for developing and applying genomic sciences that create economic wealth and social benefit
for Canadians. Genome Canada builds bridges between government, academia and industry to forge a genomics-based public-private
innovation enterprise focused on key life science sectors (agriculture, fisheries, forestry, energy, mining, environment, and
human health). Genome Canada and the regional Genome Centres have made significant investments in large-scale genomics1
research and leading-edge technologies which has allowed Canada to become a leader in the field of genomics. We are now
focusing a significant amount of effort to build and improve ways of translating discoveries into new applications by
enabling the transfer of knowledge and technologies from Academia to the User community in ways that will maximize the
impact of this initial investment and lead to economic and social benefits for Canada.
The GAPP aims to:
Promote the application of genomics-derived solutions to address key sector challenges or opportunities facing Users - User “pull”;
Promote commercialization of genomics technologies by enabling the transfer of genomics-derived solutions from Academia to Users as
well as de-risking and incentivizing follow-on investment from public and private partners;
Increase the socio-economic impact of genomics research by accelerating its translation to application or market; and,
Create and foster a more productive interface between Academia and Users.
Up to $30 million is available from Genome Canada for this program
Genome Canada will provide support for small-scale proof-of-concept or pilot projects through to large-scale projects,
ranging in size from $300,000 to $6 million in total project budget, with the Genome Canada investment not to exceed
more than 1/3 of the total investment in the project by all parties. The remaining 2/3 must be secured through co-funding
(see Section 9 and Appendix 2 for more details on co-funding)
Generally, the project term should be a minimum of six months to a maximum of three years. A shorter or longer term will
be considered, but only if a strong rationale is provided.
4. Project Eligibility
To be eligible for funding, proposals must:
Respond to the objectives of the GAPP
Represent an active partnership between Academic(s) and User(s) (see Section 5);
Propose to develop, enhance or validate a genomics-derived solution(i.e., a product,
tool or process whose origin is based in genomics);
Address key challenges or opportunities defined by the User that require a partnership with Academia (i.e., User “pull”); and
Focus on downstream R&D activities.
Examples of downstream R&D include proof-of-concept, validation or product/tool development projects for which there is a significant
commercial market potential for the product, tool or process to be developed, enhanced or validated or other measurable impacts, such as
uptake into practice or policy. The GAPP will support projects that have direct or indirect impacts on human health or have socio-economic
benefits in other sectors of importance to Canada’s economy, e.g., agriculture, fisheries, forestry, energy, mining and the environment.
The GAPP is intended to fund projects that enable the transfer of knowledge and technologies from Academia to Users and require support
from Genome Canada to de-risk and incentivize follow-on investment from public and private partners. The GAPP is not intended to provide
- Discovery research projects;
- The commercial launch of a new product, tool or process; or,
- Projects that would normally be funded solely by the User (e.g., industry).
5. Project Partners
There are two categories of partners in GAPP projects: Academics and Users. The roles and responsibilities of each Project Partner in arriving
at the anticipated outcome(s) must be clearly defined. To be eligible for funding, each project must represent an active partnership between the
Academic and the User. An active partnership is defined as one that leverages the resources of the Partners. It is expected that the Academic
will provide expertise and knowledge with respect to the genomics-derived solution proposed. It is expected that the User must provide leadership
in the identification of: the key issues to be solved; platforms, services or products to be developed; and, how these platforms or services would
be exploited or moved forward. Partners must, individually or collectively, have a demonstrated track record of achieving results and translating
discoveries to market or application. The proposal must be co-led by an Academic and an individual from the User organization(s) to demonstrate
commitment, leadership and active partnership.
An Academic is defined as an independent investigator who is a faculty member employed by a Canadian post-secondary organization or their
affiliated institutions including hospitals and research institutes. Researchers from not-for-profit organizations may be considered the
Academic Project Partner if the organization has an explicit research mandate.
Users include companies, industry consortia, government departments or agencies, or not-for-profits that have a credible plan for exploiting
project results for the socio-economic benefit of Canada. The User must show that it has the expertise and resources to put the plan into
effect or the means, as well as the intention, to acquire this capacity.
A company is defined as a private or public, Canadian- or foreign-owned organization that derives the majority of its revenues from the sale
of products and services and not from government aid. Small or start-up companies (companies in the R&D phase) that have sound business
plans may be accepted as Users. For researcher-owned companies, the company must demonstrate that it has its own facilities and staff,
physically separated from the academic researcher's laboratory (e.g., located in a university incubator facility or off campus).
5.2.2. Other Users
Other Users, including government departments and agencies, industry consortia and not-for-profits are eligible if they are in a position to
exploit the results of the project in a way that results in significant socio-economic benefit to Canada.
6. Socio-Economic Benefits
The proposed socio-economic benefits to Canada must be significant, e.g., providing a competitive advantage to Canadian industry, improving public
policy, or enhancing the cost-effectiveness of the healthcare system.
All proposals must describe, with supporting evidence and using clearly defined and quantifiable milestones:
- The deliverable(s) to be realized by the end of the project;
a plan which explains the next steps of how the deliverables from the project will be transferred, disseminated, used, and/or applied to
realize the socio-economic benefits in as short a time as possible following completion of the project (i.e. within 3-5 years);
Who will benefit from the project, including how the deliverables will benefit the User partner;
The market potential for the product, tool or process to be developed or other measurable impact; and,
For applicable projects, e.g., those targeting commercialization, how the project deliverables will incentivize follow-on investment
from public and/or private partners, enable rapid progress towards the marketplace, and ensure further return on investment.
Proposals must take into account any societal issues (environmental, economic, ethical, legal and social) that may impact the success of the
project or potentially delay uptake into practice. See Appendix 1 for more details on all review criteria.
7. Intellectual Property
As negotiation of issues related to intellectual property (IP) is anticipated to be critical to the finalization of contracts between
the Academic(s) and the User(s), at the time of submission of a full proposal, applicants will be required to provide a non-legally binding
Term Sheet. The Term Sheet must address the following issues:
- Ownership of ‘foreground’ IP generated by the project;
- Rights to use ‘background’ IP required for use in the project;
- Licences to use foreground and background IP to the different project participants;
- Management issues related to foreground IP (such as patent expenses, patenting decisions, dividing fields and scopes of use); and,
- Risk management issues (what special risks might be present in this project and on which project participant do those risks fall).
Genome Canada does not take an ownership stake in project IP; however, in funding projects within GAPP, Genome Canada expects any intellectual
property created or developed within a Project to be exploited, including licensing, in a way that maximizes benefits for Canada. Ownership
of IP created or acquired as part of projects in which Genome Canada is directly or indirectly involved shall be in accordance with each of
the participants’ (i.e., Federal or Provincial government departments or Crown Corporations, private sector companies, universities,
research hospitals or any other participants) internal IP policies and Provincial and or Federal legislation, if applicable
(refer to Genome Canada’s Intellectual Property Policy). Applicants should also contact
their Genome Centre for information on specific Genome Centre guidelines related to IP.
8. Application Process
There is a two-stage application process for this program:
- Expression of Interest (EOI)
- Full Proposal
EOIs and full proposals must be submitted to Genome Canada through a Genome Centre (see Contacts, Section 10) and will be accepted on a
rolling intake basis, until all funding has been committed. The application process may be adjusted where warranted by relevant factors
such as the level of interest in the program. Any changes will be rapidly communicated through Genome Canada’s website and through the
8.1. Expression of Interest
Applicants are required to submit an Expression of Interest (EOI) to Genome Canada (through their Genome Centre). The EOI will be reviewed
by the Genomic Applications Programs Portfolio Manager (GAP PM) to determine eligibility for the program. Applicants will normally be
informed within two weeks whether their application is considered eligible, the timing of upcoming meetings of the Core Evaluation Team
(CET) and the deadlines for submission of a full proposal for consideration at each meeting.
EOI submissions to the program will be accepted on or after July 29, 2013. For details about the timing of upcoming CET meetings and
deadlines for submission of full proposals, please refer to the Timelines available on Genome Canada’s website.
8.2. Full Proposal
The full proposals will first be reviewed by the GAP PM. A final check for eligibility will be carried out as well as an assessment as to the
extent to which the proposal addresses all the Evaluation Criteria (refer to Appendix 1). Based on this evaluation, the GAP PM will determine
whether the proposal is ready to undergo a Due Diligence review or whether further development is required by the applicants and Genome Centres.
8.2.1. Due Diligence
The Due Diligence will be undertaken by a small team of experts, specifically selected based on their expertise and experience in reviewing the
financial, management and technical aspects of proposals such as those being submitted to this program. They will assess the proposal based on
the Evaluation Criteria (see Appendix 1) and make recommendations to the CET. In cases where a thorough Due Diligence has been undertaken by
the User, co-funder or another organization the GAP PM will determine whether it covers the same criteria and is sufficient. If the Due Diligence
undertaken by the other organization is deemed sufficient, the proposal and Due Diligence reports may be forwarded directly by the GAP PM to the
CET for consideration.
8.2.2. Core Evaluation Team
Genome Canada will establish a CET composed of external experts with the expertise in business development, commercialization, public policy,
socio-economic benefit analysis, IP, financing, venture capital, etc. The CET will meet quarterly to review the proposals and the reports
from the Due Diligence reviewers and make recommendations to Genome Canada regarding funding. The CET will also be involved in the ongoing
monitoring of funded projects, as described in Appendix 2, Section 3.5.
9. Eligible Costs and Co-Funding
The main categories of eligible costs are: i) salaries and benefits, ii) consumables, iii) equipment, iv) administrative costs and iv)
services from others. Genome Canada funds may be used to cover eligible costs incurred by the Project, with the exception of costs
incurred outside Canada or within organizations that are not eligible to receive Genome Canada funding, i.e., companies or federal
government departments and agencies.
Genome Canada will invest up to 1/3 of the funding required to cover eligible costs; the remaining 2/3 must be secured through
co-funding with at least 1/3 provided by the User. The Genome Centres, working with the applicants, are responsible for securing
co-funding. Co-funding must be for new or incremental activities that are an integral part of the Genome Canada approved project.
For more details on eligible costs and co-funding, refer to Appendix 2.
Appendix 1. Evaluation Criteria
1. Eligibility Criteria
The proposal must:
- Respond to the objectives of the GAPP
- Represent an active partnership between Academic(s) and User(s)
- Propose to develop, enhance or validate a genomics-derived solution, i.e., a product, tool or process whose origin is based in genomics
- Address key challenges or opportunities defined by the User that require a partnership with Academia (User “pull”); and,
- Focus on downstream R&D activities.
2. Due Diligence Criteria
2.1. Technical Aspects
- Feasibility of the technical aspects of the proposal
- Suitability of the available facilities, equipment and services for carrying out the project
- Technical expertise of team
- Ability to achieve deliverables in timeframe proposed
- Degree to which the proposal enables the transfer of knowledge and technologies from Academia to the User community
2.2. User Relevance and Benefits to Canada
Provides significant socio-economic benefit to Canada in the near term (i.e., three to five years), by, for example,
providing a competitive advantage to Canadian industry, improving public policy, enhancing the cost-effectiveness of
the healthcare system, etc.
Significant market potential for the application, or other measurable impact
The next steps after the end of the project are well-defined such that the deliverables of the project are likely to be exploited for
the socio-economic benefit of Canada in the near term.
Extent to which the commercialization strategy is well-defined and reasonable, including IP handling. If the application is not
commercial, how well defined and reasonable is the strategy for uptake into policy or practice?
Reasonableness of the IP Term Sheet
2.3. Ability to Deliver on Objectives
- Credibility of plan proposed by User for exploiting results of the project for the socio-economic benefit of Canada
- Expertise and resources of the User to put the plan into effect, or the means, as well as the intention, to acquire this capacity
- Extent to which the project team has all the required expertise to address the defined objectives competently and to complete the project successfully
- Extent to which the impediments to application or uptake of the product, tool or process are addressed, e.g., regulatory hurdles or societal aspects
2.4. Management and Financial Aspects
Quality of the management team
Effectiveness of the management plan with respect to project governance, accountabilities of personnel,
and processes for decision- making on research direction and strategy for realizing benefits
Milestones proposed are well-defined and quantifiable. Go/no go milestones are clearly articulated
Reasonableness of the proposed budget in terms of the anticipated level of effort and deliverables
Extent to which the proposal provides assurance that expenditures from a funded project will be closely and critically monitored
User is providing at least 1/3 of the co-funding
Extent to which the proposed co-funding plan is well-documented, eligible and feasible
Proposed co-funding is integrated with and directly supports the objectives of the project
Likelihood that all the co-funding will be secured at the time of release of funds
Appendix 2. Guidelines for GAPP Projects
1. Project Partners
Academic Project Leader
Each project must identify a Project Leader from an Academic Institution (see 5.1. Academics of the Investment Strategy).
The Academic Project Leader is responsible for the intellectual direction of the proposed project and assumes administrative and financial
responsibility for funds that will be paid to his/her institution.
User Project Leader
In addition to the Academic Project Leader, teams must identify a Project Leader from the User partner (see 5.2. Users in
the Investment Strategy) organization to demonstrate commitment, leadership and active partnership. The User Project Leader is also
responsible for the intellectual direction of the proposed project and assumes administrative and financial responsibility for the
expenses incurred within their organization. The User Project Leader must be in a position to influence decisions made by the User
organization and dedicate sufficient time to the project to be actively involved in its intellectual direction. The Academic Project
Leader and the User Project Leader cannot be the same person.
An Academic Co-applicant is a team member from an academic institution who makes a substantial contribution to the proposed project
and who will be involved in the day-to-day execution of the project.
A User Co-applicant is a team member from a User organization who makes a substantial contribution to the proposed project and who will be
involved in the day-to-day execution of the project.
A Collaborator is an individual who is not involved in the day-to-day execution of the project but whose role is to provide a specific
service or expertise (e.g., access to equipment, provision of specific reagents, training in a specialized technique, statistical
analysis, access to a patient population, etc.).
2.1. Eligibility of Investigators, Institutions and Organizations
Genome Canada funding is restricted to work performed within Genome Canada eligible institutions, i.e., Genome Canada will not support
work to be undertaken outside Canada, in for-profit organizations or in federal laboratories, except for costs incurred based on a
reasonable fee-for-service arrangement or contract.
Genome Canada funds can be awarded to investigators affiliated with the following institutions and organizations:
Canadian post-secondary organizations and their affiliated institutions including hospitals and research institutes;
Canadian non-federal government departments or agencies and not-for-profit organizations (including community or charitable
organizations) with an explicit research or knowledge-translation mandate.
2.2 Eligible Costs
Eligible costs are defined as reasonable costs for items that directly support the objectives of the Genome Canada approved project.
Budgets must NOT include items for which funding has already been approved from other sources, unless the request for funding of these
items was specifically made to support activities in the Genome Canada project and they meet all other eligibility criteria. Expenses
funded through Genome Canada must be incurred after the Notice of Award (NOA) to be considered as eligible costs. However, expenses
covered by eligible co-funding incurred up to three months prior to the NOA may be considered eligible costs.
Eligible costs may include the following:
Salaries and benefits for project team members (note that salaries of independent investigators who are faculty members of academic
institutions or in a management role in a User organization are not considered eligible costs).
The actual benefit rates as charged by the host organization. For benefit rates that exceed 20% of the employee’s salary supporting
documentation (such as a letter from the organization`s human resources department) must be provided.
The actual cost of release time from teaching and clinical duties, if supported by a letter from the host institution.
Annual inflation for salary expenditures in the second and later years of the project at actual rates as charged by the organization;
for inflationary increases exceeding 1.5% of total salary and benefits, supporting documentation must be provided.
Equipment is defined as any item (or interrelated collection of items comprising a system) which is used wholly or in part for the
work proposed and meets all three of the following conditions: 1) nonexpendable tangible property; 2) having a useful life of more
than one year; and, 3) a cost of $2,000 or more.
Small equipment items having a value of less than or equal to $50,000 each are eligible; more expensive items will only be covered
in exceptional circumstances when the equipment is crucial to the success of the project and the equipment cannot reasonably be
funded by other sources or accessed by other means.
Please note that the costs of equipment maintenance contracts and general maintenance of research infrastructure are considered
consumables expenses (see below).
Material and supplies: includes items that meet at least one of the following conditions: 1) expendable tangible property; 2) useful life
of one year or less; or, 3) a cost of less than $2,000. As an example, a laptop computer that costs less than $2,000 would be considered a
consumable even though it is a nonexpendable tangible item with a useful life of more than one year.
The consumables category also includes items such as equipment maintenance contracts and general maintenance of research infrastructure,
travel directly related to the conduct of the project, and materials and supplies related to the direct costs of application or commercialization
activities (e.g., costs associated with advancing development of products and technology, business case development, market research and
General and Administrative Costs
Administrative costs can include, for example, travel for project team members related to the management of the project (e.g., project team
meetings) and project-related conferences, communications and public outreach activities, website maintenance, office expenses, costs
associated with the preparation of reports.
Administrative costs must not exceed five percent (5%) of the non-administrative costs of the budget.
Services from Others
- The costs related to services provided by fee-for service providers.
Expenses related to application or commercialization activities provided on a fee-for-service basis (e.g., patent registration and
filing costs, costs associated with advancing development of products and technology, business case development, market research
and technology evaluation).
Examples of ineligible costs include the following:
Payments to foreign persons, for example, salaries and benefits of project team members;
Indirect costs to the project, including institutional overhead costs;
Rent, renovation or construction of buildings or facilities, and the opportunity cost of using existing infrastructure;
Incorporation and legal costs associated with a new spin-off or company; and,
Inflation applied to consumables, equipment, general & administrative costs or services from others.
Genome Canada will invest up to 1/3 of the investment required to cover eligible costs; the remaining 2/3 must be secured through
co-funding with at least 1/3 provided by the User. The co-funding provided by the User may be derived from their own resources or
from funds provided to the User by another source. All co-funding must be secured before funds can be released to the project. The
Genome Centres, working with the applicants, are responsible for securing co-funding.
2.3.1 Sources of Co-funding
Eligible co-funding sources include:
- Venture capital or other investment funds.
- An industry consortium
- Institutional funds, trust funds, or foundations
- Charities and philanthropic organizations
- Departments and agencies of the federal government (e.g., Natural Resources Canada, Agriculture and AgriFood Canada, the Canada Foundation for Innovation and Economic Development Agencies)
- Centres of Excellence for Commercialization and Research (CECRs)
- Departments and agencies of provincial and municipal governments
- Voluntary organizations
Ineligible co-funding sources include:
- Canadian Institutes of Health Research (CIHR)
- Natural Sciences and Engineering Research Council (NSERC)
- Social Sciences and Humanities Research Council (SSHRC)
- Canada Research Chairs (CRC)
- Networks of Centres of Excellence (NCEs); with the exception that CECRs are considered eligible for this program, see above
2.3.2 Co-funding Requirements
Co-funding must be for eligible costs that represent new or incremental activities that are an integral part of the Genome Canada approved
project (see Eligible Costs, Section 2.2) in order to be considered as an eligible co-funding source.
In-kind contributions, defined as non-cash eligible budget items which can be given as cash value (such as salaries for company personnel
working on the project) may be considered as co-funding if:
- The value can be reasonably determined and supported by documentation from the co-funder; and,
- The expenditure represents an item that would otherwise have to be acquired with cash. However, this excludes the cost of pre-existing
facilities or equipment (i.e., budgets cannot include the opportunity cost of space or equipment).
The value of existing IP transferred to a project is NOT considered eligible co-funding unless it is a contribution by a supplier of IP
(e.g., a software license that would otherwise have to be acquired from a third party supplier). Such items must be supported by appropriate
documentation from the supplier’s head office.
Suppliers’ discounts are not considered eligible co-funding.
Funding to support the indirect costs of a project (including overhead) are not eligible.
2.3.3 Documentation Required to Support Co-funding
Full applications must include complete documentation to support proposed co-funding. This may be in the form of a letter of commitment or an
agreement defining the terms and conditions of proposed co-funding. In addition, the project must provide a description of how the co-funding
will directly support the objectives of the Genome Canada project. In general, co-funders must explicitly acknowledge the use of funds to co-fund
the Genome Canada projects.
The following provides specific examples of documentation required, depending upon the co-funding source, or type:
Organizations, including companies, charities, and philanthropic organizations:
Documentation and supporting information which clearly demonstrates the organization’s level and terms of commitment to the project.
Appropriate documentation could include but is not limited to a Board Resolution, and/or, a letter from the organization’s CEO, legal
counsel or Corporate Secretary.
Appropriate and reasonable documentation supporting the organization’s financial viability and its ability to deliver on the co-funding.
Depending on the organization and the level of funding being committed, documentation could include: A full set of the organization’s
most recent audited financial statements, including the Auditor’s Report, a Balance Sheet, Income Statement, Statement of Cash Flows
and Notes to the Financial Statements
In the case where the audited statements are more than three months old, a full set of the organization’s financial statements (prepared
within three months prior to the application) including a Balance Sheet, Income Statement, Statement of Cash Flows and Notes to the Financial
Any other information or documentation (e.g., press releases announcing significant new financing, cash flow projections, etc.) which
provides credible support to the organization’s financial viability and ability to fulfill its co-funding commitments.
From a Provincial government
- Confirmation that the province will provide co-funding
- The amount anticipated
A list of other projects currently submitted to the GAPP that the government will support, including the project tracking number,
the name of the Project Leaders, the title of the project, and the amount of the request from the government;
A description of the process that will take place once Genome Canada announces awards, including timelines for decisions and, if
appropriate, confirmation that the government will accept Genome Canada's review process; and,
A letter signed by a high-ranking provincial government official with appropriate authority.
From a funding agency
- A copy of the full application
- Project summary
- Detailed budget; and
- Notice of award (if applicable)
Documentation must clearly demonstrate that funding is being used for eligible costs included in the budget of the Genome Canada approved project.
A clear rationale and calculation of how the value of the contribution was determined (including documentation to support all
assumptions, price lists, quotes from suppliers, letters supporting same, etc.).
All in-kind contributions must be auditable by outside experts and clear explanations are required if there are any discrepancies between
the value outlined in the co-funding document and the budget. Examples of supporting documentation to support in-kind co-funding include:
Each in-kind salary line must be detailed by position as required in the budget template and represent the actual salary and
benefits of the position in accordance with the applicable salary provisions of Eligible Costs in section 2.2.
Documentation that indicates the actual cost to the User or co-funder to acquire the consumables or documentation that
indicates the price that would be typically paid for the item(s) on the commercial market.
- Equipment and Software
Letter from a senior official of the vendor that shows the price that the customer would typically have paid for the
equipment or software (net of typical discounts including institutional discounts which are not eligible as co-funding)
For custom-made or used equipment, a third party valuation will normally be required
For previously developed custom-made software or IP, only new costs are eligible.
- Samples and Other Biological Resources
If samples are typically available at no cost then there is no cost of acquiring such samples and as a result no value can be deemed to be co-funding
If samples are typically sold, then any proposed contribution would require the same documentation as equipment and software.
3.1 Project Readiness
Leader(s) of approved projects must meet, through formally submitted documentation, all relevant conditions that may be specified in the Notice
of Award (NOA) received from Genome Canada and be in a position to receive Genome Canada funding no later than three months after the effective
date of the NOA. Genome Canada reserves the right to withdraw funding for any approved project that is not ready to receive funding at that time.
3.2 Conditions for Release of Genome Canada Funds
Before funds can be disbursed the conditions for funding must be satisfied which normally include, but are not restricted to:
Signed agreements between the Genome Centre and the lead organization, the project team and the co-funding partners. The agreements must clearly
demonstrate agreement among the relevant parties, on all significant issues including but not limited to, the nature of financial contributions,
IP ownership and management in alignment with the Term Sheet submitted in the proposal, data release, the commercialization process, the funding
term, a termination policy, financial and administrative policies, and quarterly reporting of expenses and co-funding status, etc. The agreements
must be in compliance with the agreement between Genome Canada and the lead Genome Centre.
A revised budget, as well as revised objectives and milestones, if adjustments were made during the review process;
Secured co-funding (received or firmly committed) for the project (i.e. 100% of co-funding). Genome Canada reserves the right to withdraw its
funding for any approved project that does not meet this requirement or if there is a substantial change in a project’s co-funding status.
Appropriate certification for proposals performing research involving human subjects, human stem cells, animals, biohazards, radioactive materials
or possible effects on the environment are in place.
A publication policy which includes a commitment to comply with Genome Canada’s policy on Access to Research Publications.
A commitment to acknowledge the contribution of the Government of Canada through Genome Canada and the lead Genome Centre, as well as all other
relevant funders, in publications and all communications in compliance with Genome Canada’s Brand Standards Guide
3.3 Management of Funding
The agreement between Genome Canada and the Genome Centre will reference financial commitments from other persons as well as other financial requirements.
As the needs and circumstances of each Centre, the team and partner organizations may differ, the contracts between these partners will be negotiated
individually and need not be identical, but should apply the same general principles defined in the agreement between Genome Canada and the Genome Centres.
Genome Canada’s share of the funding for approved projects will flow from Genome Canada to the Centres. The Genome Centres will manage (e.g., disburse,
monitor and report on) the funds for the project.
Genome Canada’s contributions can be adjusted to accommodate the timing of the expected receipt of funds from co-funding partners.
Genome Canada provides funding up to the approved quarterly contribution, a quarter “in advance”, subject to receipt of quarterly reports of expenditures
(from both Genome Canada and co-funding sources), including actuals to the previous quarter, estimates for the current quarter, and forecasts for the
quarter of the advance. Subsequent quarterly advances may be adjusted to account for any unused funding. The final settlement of advances is based on
Genome Canada’s pro rata share of actual expenditures, as per the Genome Canada’s contribution ratio on the latest approved budget.
The financial status of co-funding (domestic and international) must be reported on a quarterly basis.
3.4 Accountability, Reporting and Performance Measurement
Funded projects must submit to their lead Genome Centre on a quarterly basis, information and data as prescribed by the Centre and the Genome Canada
in terms of timing, format and content, which will allow for the on-going assessment and monitoring of their performance. Funded projects must also
agree to participate in and provide information for any evaluation-type activities that may be undertaken from time to time by Genome Canada or the
Genome Centre, for up to five years subsequent to the end date of the project.
3.5 Monitoring, Maximizing Impact and Management of Changes to Funded Projects
In order to ensure projects are meeting their milestones and maximize the likelihood of success of funded projects, the lead Genome Centre and the
Genome Canada GAP PM will work together to monitor and advise the projects on an ongoing basis. In addition, project teams will be required to submit
quarterly reports to their lead Genome Centre, including reporting on progress towards meeting their milestones. For projects in which the investment
from Genome Canada is less than $1 million and there was no go/no go gate in that quarter, the GAP PM will review the progress report and provide
feedback directly to the project via the lead Genome Centre. For projects where the investment by Genome Canada is greater than $1 million or
for any project where there is a go/no go milestone during that quarter, the progress reports will be forwarded to the Core Evaluation Team.
Each quarter, the CET will make recommendations to Genome Canada regarding whether funding should be continued, modified or cancelled for those projects.
Over the term of a Genome Canada funded project, changes to the scientific, managerial or financial conditions of funding initially approved by Genome
Canada must be discussed in advance with the Lead Genome Centre and the Genome Canada GAP Portfolio Manager. Changes may be submitted to the
CET for review. Final approval of changes will be required from the Lead Genome Centre and Genome Canada.
3.6 Final Reports
Within three (3) months of the completion of the projects, each project will be required to submit to its Genome Centre a final report
that includes a description of the accomplishments of the project relative to the approved objectives as well as a detailed financial report in
a format as determined by Genome Canada. A percentage of the final payment will be held back pending receipt and approval of the Final Report.
EOIs will be accepted on or after July 29, 2013
Cut-off dates for submission of full proposals to be considered at upcoming Core Evaluation Team (CET) meetings are:
- October 11, 2013 (for consideration at mid-November 2013 CET meeting)
- January 10, 2014 (for consideration at mid-February 2014 CET meeting)
 The term genomics is defined here as the comprehensive study, using high throughput technologies, of the genetic information
of a cell or organism, including the function of specific genes, their interactions with each other and the activation and
suppression of genes. For purposes of describing Genome Canada’s mandate it also includes related disciplines such as bioinformatics,
epigenomics, metabolomics, metagenomics, nutrigenomics, pharmacogenomics, proteomics and transcriptomics.